在前性痴呆和阿尔茨海默氏症和帕金森病中,共享和疾病特异性途径
Muhammad Ali1,2, Buddhiprabha Erabadda3, Yike Chen1,2
1Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Nature medicine
|July 15, 2025
概括
这项研究分析了像阿尔茨海默氏症和帕金森氏症这样的神经退行性疾病 (ND) 的血蛋白质组学. 它确定了共享和独特的蛋白质签名,揭示了潜在诊断和治疗的共同途径和疾病特异性机制.
科学领域:
- 神经科学是一个神经科学.
- 蛋白质组学是指蛋白质组学.
- 生物化学 生化学
背景情况:
- 神经退行性疾病 (NDs) 如阿尔茨海默氏症 (AD),帕金森病 (PD) 和前性痴呆症 (FTD) 分享复杂的病理机制.
- 了解这些共同和独特的途径对于开发有效的诊断和治疗策略至关重要.
研究的目的:
- 通过大规模的血蛋白学,在AD,PD和FTD中识别疾病特异性和共享蛋白质.
- 阐明常见和分歧的蛋白质组特征以及神经退行症中潜在的生物学途径.
主要方法:
- 分析了来自AD,PD,FTD,痴呆症和对照患者的10,527个血样本.
- 利用来自全球神经退行性蛋白质组学联盟的大规模等离子体蛋白质组学数据.
- 采用多种分析方法和对已识别的蛋白质特征进行直角验证.
主要成果:
- 鉴定了AD的5,187种蛋白质,PD的3,748种,FTD的2,380种,揭示了共享和分歧的蛋白质组签名.
- 在PD和FTD之间观察到的蛋白质重叠最高 (r2=0.44),在AD和PD之间观察到的蛋白质重叠最低 (r2=0.04).
- 在所有ND中丰富的途径包括免疫系统,糖解和母体体;疾病特异性途径涉及亡 (AD),ER-phagosome (PD) 和血小板功能 (FTD).
- 确定了主要的上游监管机构:RPS27A (AD),IRAK4 (PD) 和MAPK1 (FTD).
结论:
- 该研究揭示了不同神经退行性疾病背后的独特和共享的蛋白质基因机制.
- 确定了潜在的调节蛋白和途径,这些途径可以为未来的神经退行症的诊断和治疗策略提供信息.
- 血蛋白质组学为神经退行性疾病复杂的分子景观提供了宝贵的窗口.
相关概念视频
01:15Parkinson's Disease: Overview
715
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
715
01:26Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
01:37Neural Regulation
40.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.2K
01:30Dementia
169
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
169
01:22Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263